I Will Not Be Pinkwashed: Why I Do Not Support Susan G. Komen for the Cure

by Project Censored
Published: Last Updated on

Susan G. Komen for the Cure is a multimillion-dollar company with assets totaling over $390 million  Only 20.9% of these funds were reportedly used in the 2009-2010 fiscal year for research “for the cure.” Their CEO and president, Hala G. Moddelmog, made $531,924, plus $26,683 in change. That’s more than President Obama makes. The largest chunk of the pie is going toward “public health education,” 39.1% and the health screening is 13.0%

If Komen’s mission is to find a “cure,” why are they putting over half its money toward promoting awareness and screening, for early detection of breast cancer. It’s not curing breast cancer to find out that you have cancer and treat it in the early stages in hopes of entering into remission. That’s not a cure. Yet that is Komen’s largest promoted focus. While that may be considered a worthwhile goal to some, it’s important to realize that Komen stands to profit from spreading that message.

Susan G. Komen for the Cure only spends 11% of it’s total revenue on research funding. Donate a dollar “for the cure?” Only about a dime of that will go toward research that might actually be designed to cure cancer, through allopathic medicine that is driven by the pharmaceutical system.

The organization’s biggest sponsors are the corporations that profit through cancer treatments – namely chemotherapy and radiation.  Is Komen for the Cure really about finding a cure for cancer, or is it about selling more drugs and radiotherapy that keeps more patients locked into a cycle of dependence and toxic cancer treatments?

Title: “I Will Not Be Pinkwashed: Why I Do Not Support Susan G. Komen for the Cure”

Author: Emily MichellePublication: ButterBeliever.com

Date of Publication:October 22, 2011

URL: http://butterbeliever.com/2011/10/22/i-will-not-be-pinkwashed-why-i-do-not-support-susan-g-komen-for-the-cure

 

Student Researcher: Itatiaia Daniel, San Francisco State University.

Faculty Evaluator: Kenn Burrows, San Francisco State University